Surprisingly, it was observed that patients with pancreatic ductal adenocarcinoma (PDAC) who had low exo-CD40 expression had a longer survival rate compared to those with high exo-CD40 expression. This evidence concerns the gene CD40 and pancreatic ductal adenocarcinoma.